These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 528789)

  • 1. Protective efficacy of immunization with capsular antigen against experimental infection with Bacteroides fragilis.
    Kasper DL; Onderdonk AB; Crabb J; Bartlett JG
    J Infect Dis; 1979 Nov; 140(5):724-31. PubMed ID: 528789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for T cell-dependent immunity to Bacteroides fragilis in an intraabdominal abscess model.
    Onderdonk AB; Markham RB; Zaleznik DF; Cisneros RL; Kasper DL
    J Clin Invest; 1982 Jan; 69(1):9-16. PubMed ID: 6976357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a model of intraabdominal sepsis for studies of the pathogenicity of Bacteroides fragilis.
    Onderdonk AB; Shapiro ME; Finberg RW; Zaleznik DF; Kasper DL
    Rev Infect Dis; 1984; 6 Suppl 1():S91-5. PubMed ID: 6372042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infection with Bacteroides fragilis: pathogenesis and immunoprophylaxis in an animal model.
    Kasper DL; Onderdonk AB
    Scand J Infect Dis Suppl; 1982; 31():28-33. PubMed ID: 6954635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface antigens as virulence factors in infection with Bacteroides fragilis.
    Kasper DL; Onderdonk AB; Polk BF; Bartlett JG
    Rev Infect Dis; 1979; 1(2):278-90. PubMed ID: 549184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular immunity to Bacteroides fragilis capsular polysaccharide.
    Shapiro ME; Onderdonk AB; Kasper DL; Finberg RW
    J Exp Med; 1982 Apr; 155(4):1188-97. PubMed ID: 6174672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis.
    Tzianabos AO; Kasper DL; Cisneros RL; Smith RS; Onderdonk AB
    J Clin Invest; 1995 Dec; 96(6):2727-31. PubMed ID: 8675640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative determination of the antibody response to the capsular polysaccharide of Bacteroides fragilis in an animal model of intraabdominal abscess formation.
    Kasper DL; Onderdonk AB; Bartlett JG
    J Infect Dis; 1977 Dec; 136(6):789-95. PubMed ID: 336801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encapsulation and protection against phagocytosis by Bacteroides fragilis.
    Lindberg AA; Weintraub A
    Scand J Infect Dis Suppl; 1985; 46():27-32. PubMed ID: 3865350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A soluble suppressor T cell factor protects against experimental intraabdominal abscesses.
    Zaleznik DF; Finberg RW; Shapiro ME; Onderdonk AB; Kasper DL
    J Clin Invest; 1985 Mar; 75(3):1023-7. PubMed ID: 2579976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition.
    Kasper DL
    J Infect Dis; 1976 Jan; 133(1):79-87. PubMed ID: 1451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenicity of Bacteroides fragilis group in rat intra-abdominal abscesses.
    Jotwani R; Gupta U; Watanabe K; Ueno K
    Microbiol Immunol; 1992; 36(10):1041-9. PubMed ID: 1479960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell regulation of Bacteroides fragilis-induced intraabdominal abscesses.
    Crabb JH; Finberg R; Onderdonk AB; Kasper DL
    Rev Infect Dis; 1990; 12 Suppl 2():S178-84. PubMed ID: 2406870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virulence factors in Bacteroides fragilis group.
    Jotwani R; Gupta U
    Indian J Med Res; 1991 Jul; 93():232-5. PubMed ID: 1959952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains.
    Onderdonk AB; Kasper DL; Cisneros RL; Bartlett JG
    J Infect Dis; 1977 Jul; 136(1):82-9. PubMed ID: 886206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species specific monoclonal antibodies to Bacteroides fragilis lipopolysaccharide protect mice from severe infection.
    Brake B; Larcher C; Schulz TF; Prodinger W; Dierich MP
    Zentralbl Bakteriol; 1992 Oct; 277(3):320-8. PubMed ID: 1283090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological detection of Bacteroides fragilis in clinical samples.
    Patrick S; Stewart LD; Damani N; Wilson KG; Lutton DA; Larkin MJ; Poxton I; Brown R
    J Med Microbiol; 1995 Aug; 43(2):99-109. PubMed ID: 7629860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators.
    Tzianabos AO; Gibson FC; Cisneros RL; Kasper DL
    J Infect Dis; 1998 Jul; 178(1):200-6. PubMed ID: 9652441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations of Bacteroides fragilis with in vitro passage: presence of an outer membrane-associated glycan and loss of capsular antigen.
    Kasper DL; Onderdonk AB; Reinap BG; Linberg AA
    J Infect Dis; 1980 Nov; 142(5):750-6. PubMed ID: 7462689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence of Bacteroides fragilis in vivo.
    Onderdonk AB; Moon NE; Kasper DL; Bartlett JG
    Infect Immun; 1978 Mar; 19(3):1083-7. PubMed ID: 640723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.